Division Introduction

Under the direction of Stephen X. Skapek, M.D., the faculty, fellows, and numerous support and administrative staff in the Division of Pediatric Hematology-Oncology continue to be dedicated to the fulfillment of a four-fold mission:

- The diagnosis and care of infants, children, and adolescents with cancer and myriad hematologic disorders
- The education of medical students, residents, fellows, and other trainees, as well as provision of continuing education to practicing physicians
- Clinical, translational, and laboratory research aimed at improving and extending our knowledge about blood diseases and cancer
- Advocacy of our cause on behalf of the patients and families we serve

As the largest cancer and blood disease program in North Texas, and one of the largest in the United States, each year physicians in the Division provide care for more than 300 children with newly-diagnosed cancer and more than 600 children with newly-diagnosed blood disease. Care is primarily provided in the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health Children’s Medical Center in Dallas and Plano. We continue to work toward increasing our geographic footprint by increasing the scope and scale of clinical care we can provide in Plano and other suburban sites. We also continue to look for opportunities to increase regional outreach by providing educational and consultative resources for primary and referring physicians in the region.

Faculty in the Division of Pediatric Hematology and Oncology are conducting clinical as well as laboratory-based research in cancer and blood disease. Laboratory research efforts include both basic and translational studies that help to bridge the lab and clinical venues. The clinical research efforts include a portfolio of 50 or more clinical research studies extending from clinical trials sponsored by the National Cancer Institute through the Children’s Oncology Group; clinical research studies supported by other grant funding agencies, including the National Institutes of Health and the Cancer Prevention and Research Institute of Texas (CPRIT); and research studies carried out with industry partners. The research is carried out in laboratories at UT Southwestern and the Children’s Medical Center Research Institute at UT Southwestern, and clinical sites within the Children’s Health system.

Our education mission includes medical students, pediatric residents, and hematology/oncology fellows. The Division also sponsors an innovative summer student internship program for outstanding premedical and medical students.

As the largest cancer and blood disease program in North Texas, and one of the largest in the United States, each year physicians in the Division provide care for more than 300 children with newly-diagnosed cancer and more than 600 children with newly-diagnosed blood disease.
Faculty

The Division has a team of 27 faculty, and eight fellows. Four new faculty joined the team in 2018.

Erin Butler, M.D.
Assistant Instructor

- B.M., summa cum laude
  - DePaul University, Chicago, IL, 2008
- M.D.
  - UT Southwestern, 2012

**Postdoctoral Training**
- Residency, Pediatrics
  - UT Southwestern/Children’s, 2012-2015
- Fellowship, Pediatric Hematology-Oncology
  - UT Southwestern/Children’s, 2015-2018

**Interests**
- Soft tissue sarcomas

Jessica Garcia, M.D.
Instructor

- B.S.
  - University of Illinois, Urbana-Champaign, IL, 2007
- M.D.
  - University of Illinois College of Medicine, Peoria, IL, 2012

**Postdoctoral Training**
- Residency, Pediatrics
  - University of Illinois College of Medicine, Peoria, IL, 2012-2015
- Fellowship, Pediatric Hematology-Oncology
  - Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI, 2015-2018

**Interests**
- Health related quality of life outcomes in patients with bleeding disorders,
  clinical/translational research

Holly Pacenta, M.D.
Instructor

- B.A.
  - Miami University, Oxford, OH, 2008
- M.D.
  - University of Toledo College of Medicine, Toledo, OH, 2012

**Postdoctoral Training**
- Residency, Pediatrics
  - Indiana University School of Medicine, Indianapolis, IN, 2012-2015
- Fellowship, Pediatric Hematology-Oncology
  - University of Colorado School of Medicine, Aurora, CO, 2015-2018

**Interests**
- Experimental therapeutics, CAR-T
Ksenya Shliakhtsitsava, M.D., M.A.Sc.
Assistant Professor

M.D.
Belarusian State Medical University, Belarus, 2006

M.A.Sc.
University of California, San Diego, CA, 2018

Postdoctoral Training
Residency, Pediatrics
Children’s Regional Hospital of Mogilev, Belarus, 2006-2007
University of San Francisco-Fresno, Fresno, CA, 2010-2014
Fellowship, Pediatric Hematology-Oncology
University of California, San Diego, CA, 2014-2017
4th Year Research Fellowship, Pediatric Hematology-Oncology
University of California, San Diego, CA, 2017-2018

Interests
Leukemia and Lymphoma, Fertility preservation, Cancer survivorship, Reproductive health after cancer treatment completion

Honors / Awards

Promotions
- Theodore Laetsch, Associate Professor
- Tanya Watt, Associate Professor
- Kathryn Dickerson, Instructor
- Samuel John, Instructor

Best Pediatric Specialists in Dallas, D Magazine
- Daniel Bowers
- Laura Klesse
- Patrick Leavey
- Andrew Martin
- Stephen Skapek
- Tamra Slone
- Jonathan Wickiser
- Naomi Winick

Texas Super Doctors, Texas Monthly Magazine
- Kenneth Chen, 2018 Texas Rising Star
- Andrew Martin, 2018 Texas Rising Star
- Naomi Winick

Theodore Laetsch
- Rising Star Award - UT Southwestern Leaders in Clinical Excellence

Dr. Theodore Laetsch received one of the inaugural UT Southwestern Leaders in Clinical Excellence awards - the Rising Star Award. This award recognizes exceptional early career clinical faculty whose actions and activities consistently exemplify enthusiasm, commitment, professionalism, and leadership. Awardees demonstrate exceptional clinical care beyond the level expected of an early career clinician through a consistent pattern of high-quality care, clinical leadership and innovation.
**Invited Lectures**

**Victor Aquino**

- Department of Pediatrics Grand Rounds, Texas Tech University Health Sciences Center, Lubbock, TX, April 2018
  - “Update of Childhood Low-grade Gliomas”

**Theodore Laetsch**

- Cancer Drug Development Forum (CDDF) 10th Annual Alpine Conference, Innsbruck Austria, February, 2018
  - “Clinical Development of Larotrectinib”
- United States and Canadian Academy of Pathology 107th Annual Meeting, Vancouver, Canada, March, 2018
  - Session Moderator: “Identifying the Rare: Evolving Diagnostics Standards in Characterizing Cancer”
- Children’s Oncology Group Annual Meeting, St. Louis, MO, April 2018
  - “A Pediatric Phase I Study of Larotrectinib, a Highly Selective Inhibitor of the Tropomyosin Receptor Kinase (TRK) Family”

**Ayesha Zia**

- 50th Annual Kenneth C. Haltalin Pediatrics for the Practitioner, Irving, TX, April 2018
  - “Heavy Menstrual Bleeding in Young Women: Causes and Consequences”
- The Neonatal & Pediatric SSC of the International Society of Haemostasis and Thrombosis, Dublin, Ireland, July 2018
  - “Update on Appropriate and Necessary Care for Adolescents with Heavy Menstrual Bleeding and Bleeding Disorders”

**Conference Presentations**


Oral Presentation, ASPHO Annual Meeting, Pittsburgh, PA, May 2018
“Phase 1 Study of the EZH2 Inhibitor, Tazemetostat, in Children with Relapsed or Refractory INI1-Negative Tumors Including Rhabdoid Tumors, Epithelioid Sarcoma, Chordoma; and Synovial Sarcoma”

Laetsch TW, Maude SL, Grupp SA, et al.

Oral Presentation, ASPHO Annual Meeting, Pittsburgh, PA, May 2018
“Tisagenlecleucel (CTL019) Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia”

Shweta Murthi S, Tweed J, Greenwell C, Zia A, Raman L.

Poster Presentation, Pediatric Academic Society, Toronto, Canada, May 2018
“Acute Traumatic Coagulopathy: Assessing Risk Factors Among Subgroups”

**Education and Training**

The Division of Pediatric Hematology and Oncology continues to provide educational opportunities for medical students and pediatric residents, in addition to our ACGME-accredited fellowship program in Pediatric Hematology/Oncology. Our goal is to impart knowledge, instill excitement for learning, and translate important clinical questions into focused areas of research.
Medical Students

The Division of Pediatric Hematology-Oncology continues to embrace its education of medical students at UT Southwestern through inpatient and outpatient experiences.

Third-Year Medical Students

During their third year, medical students from UT Southwestern spend eight weeks in pediatrics training at Children’s Medical Center Dallas, located on the UTSW campus. Approximately one-fourth of these students will spend two weeks on the Inpatient Hematology/Oncology Service. During this time, the students learn about and participate in the care of children with a wide range of hematologic and oncologic disorders, including sickle cell disease, hemophilia, aplastic anemia, leukemia, lymphoma, brain tumor, bone tumor, and other childhood cancers.

Fourth-Year Medical Students

Fourth-year medical students have the option to participate in a four-week elective in the outpatient hematology/oncology clinics in the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s. During this elective, the students see children with cancer and blood disorders, as well as new patients referred to the Gill Center for further evaluation. This outpatient rotation allows the students to see these children in the clinic setting to complement learning in the inpatient area, where our children are often more acutely ill. With prior approval, this elective is also available for a limited number of fourth-year students from other medical schools.

Residents

Pediatric Hematology-Oncology is one of the core subspecialties for pediatric residents at UT Southwestern. All PL-1’s spend four weeks covering the Inpatient Hematology/Oncology Service at Children’s. Each month a PL-2 or PL-3 supervising resident and two or three PL-1s are assigned to the service. The month spent on the rotation allows residents to learn to take care of what can be very complicated and sick patients with life threatening disease. Residents often look back on this time as a very rewarding experience.

Division faculty are consistently praised by the residents for their devotion to education. Over the course of the four-week rotation, several afternoons each week provide enhanced learning opportunities which may include lectures, pathology review, and bedside teaching. The curriculum covers most, if not all, of the American Board of Pediatrics Content Specifications for "Disorders of the Blood and Neoplastic Disorders."

Pediatric residents may also elect to spend a month in the outpatient clinic at the Gill Center during their second or third year. This month allows the residents to learn about, and help care for, children with a wide range of hematologic or oncologic conditions to which they may never be exposed in the inpatient setting. Over the course of the month, the residents spend time in a number of clinics, including general hematology, hemophilia, thrombosis, general oncology, neuro-oncology, and stem cell transplantation. They are also invited to attend the many educational programs offered by the Division, including weekly hemostasis and sickle cell team meetings, hematological malignancy and solid tumor patient care conferences, a weekly research seminar, and tumor board.

Fellows

The Division provides an excellent opportunity for clinical fellowship training. Children’s Medical Center Dallas, our primary pediatric teaching hospital, is the principal site for clinical training of our fellows. Directly adjacent to the UT Southwestern Medical Center, this hospital is consistently ranked by US News and World Report as one of the nation’s finest children’s hospitals. Importantly, its proximity to UT Southwestern allows clinical fellows to easily move between clinical and research training venues during their fellowship.
The Division prides itself on an atmosphere that welcomes new ideas, change, and creativity for fellowship education. The overall goals and objectives for pediatric hematology/oncology fellows are to gain extensive experience in the diagnosis and ongoing care of children with cancer and hematologic disorders, and to become researchers and teachers of pediatric hematology/oncology.

**Fellow Research**

Our Division includes physician scientists and clinical researchers with funded and successful clinical and laboratory research programs. We provide the opportunity to obtain clinical, translational or basic laboratory research training at an institution that hosts a dazzling array of world renowned investigators including distinguished faculty who are Nobel laureates and many more who are members of the National Academy of Sciences, the Institute of Medicine, and the Howard Hughes Medical Institute. Nearly all of our fellows secure funding to support or, in some cases, to extend their research training. The numerous institutional resources enabling their ability to secure finding include a Physician Scientist Translational Cancer Research T32 grant through the UTSW Simmons Cancer Center, an NCI designated Comprehensive Cancer Center.

**Research Activities**

Many faculty members of the Division of Pediatric Hematology/Oncology carry out laboratory and clinical research that is helping to reveal fundamental aspects of disease biology and beginning to lead to new, better therapies. Examples below represent just a sampling of that research.

**Laboratory Research**

Faculty are conducting molecular and cellular biology experiments in cancer and blood disease. Laboratory research efforts are both basic and translational studies that help to bridge the lab and clinical venues. Research is carried out in laboratories in the Division of Hematology/Oncology and also across the entire UT Southwestern Medical Center campus, including the NCI-designated Simmons Comprehensive Cancer Center and the Children’s Medical Center Research Institute at UT Southwestern. Laboratory research projects are funded by a variety of mechanisms including research grants from the NIH National Cancer Institute and the Cancer Prevention and Research Institute of Texas.

**Active areas of basic research in the Division include:**

- Using fruit fly and zebrafish models to understand the genetic defects causing rhabdomyosarcoma, Ewing sarcoma and malignant germ cell tumor
- Using complementary pre-clinical models to dissect the key “vulnerabilities” in rhabdomyosarcoma, Ewing sarcoma, and other soft tissue sarcomas
- Understanding the molecular machinery by which normal cells can undergo “senescence” as a tumor suppressor mechanism in the presence of a cancer-causing oncogene
- Using novel computational approaches to nominate proteins that can be “targeted” as cancer therapeutics and gene-editing approaches, like CRISPR/Cas9, to validate their importance in pre-clinical models.
- Understanding how certain cancer-causing mutations influence the metabolism in childhood brain tumors and certain types of sarcoma
Uncovering how hematopoietic and embryonic stem cells are controlled and how the control mechanisms can go awry in cancer and blood diseases, including bone marrow failure syndromes

- Elucidating the molecular machinery that guides erythrocyte development
- Using novel model systems to elucidate the host and bacterial factors that cause invasive bacterial and fungal infections
- Developing new integrated computational analysis pipelines and applying Artificial Intelligence tools to interrogate molecular genomics and transcriptomics data as well as whole-slide digital pathology images.
- Applying laboratory-based research tools to define prognostic determinants for outcomes in children with hemophilia and venous thromboembolism.

Clinical Research

Physicians in our Division are engaged in a wide range of clinical research efforts spanning the cancer and blood disease programs. Clinical research efforts are supported by robust infrastructure provided by the Clinical Research Office (CRO) within the Gill Center and the Simmons Comprehensive Cancer Center at UT Southwestern, the only NCI-designated comprehensive cancer center in North Texas. At any point, 50 to 75 oncology trials and 20 to 30 hematology trials are open for enrollment for Gill Center patients. Clinical research projects are funded by a variety of mechanisms including funding from the NIH National Cancer Institute and the Cancer Prevention and Research Institute of Texas as well as other local and regional grant funding agencies and industry partners.

Particularly notable clinical research accomplishments in this past year focus on cancer. Our center was among only approximately 12 sites in the US that helped to demonstrate the usefulness of Kymriah, a CAR T-cell therapy targeting CD19-positive relapsed B-cell leukemia in children. Kymriah is now approved for this indication by the US Food and Drug Administration (FDA). In addition, Dr. Ted Laetsch, Assistant Professor of Pediatrics, was a lead investigator helping to develop LOXO-101 (larotrectinib) for children with cancer driven by TRK gene fusions. This drug was recently approved by the US FDA for TRK-fused cancers. Our Experimental Therapeutics Program continues to identify and develop new early-phase clinical trials for children with cancer and blood disease.

Also notable, our site has joined the Neurofibromatosis (NF) Clinical Trials Consortium, a nationwide consortium of approximately 20 sites funded by the US Army Medical Research and Materiel Command. This selection enables Dr. Laura Klesse, Assistant Professor of Pediatrics, to provide the newest therapies in the form of clinical trials to children with neurofibromatosis, a neurodevelopmental and cancer predisposition syndrome.

Finally, this year marked the initiation of a nascent Precision Medicine Program, co-led by Drs. Klesse and Kathleen Ludwig, Assistant Professor of Pediatrics, as a multifaceted program to identify causes of cancer in individual children and use that information to provide more “precise” therapies.

Active areas of clinical research include:

- Prospective clinical trials for children with cancer, conducted under the umbrella of the NCI-sponsored Children’s Oncology Group
- Prospective, early-phase clinical trials for children with hematological malignancies, conducted as part of the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium and other academic and industry partners
- Prospective therapeutic trials for children with sickle cell disease, iron deficiency anemia and hemophilia
Investigator-initiated and industry-sponsored therapeutic studies of children with cancer and blood disease
Retrospective research studies investigating molecular and clinical factors influencing late effects in childhood cancer survivors
Prospective and retrospective studies assessing a variety of quality measures of children with chronic hematology disorders
Early phase clinical trials of immunotherapeutics for childhood cancer, including the use of CAR T-cells for childhood leukemia
Prospective and translational research trials in children with venous thrombosis
Clinical research in neurofibromatosis conducted as part of the national NF Clinical Trials Consortium
Robust institutional Experimental Therapeutics and Precision Medicine Programs for children with cancer

The following list contains clinical studies approved by the Institutional Review Board (IRB) at UT Southwestern as of December 31, 2018, and excludes more than 70 Children’s Oncology Group (COG) trials.

James Amatruda

- Archival Studies on Germ Cell Tumor Specimens

Victor Aquino

- Center for International Blood and Marrow Transplant Research (CIBMTR) - Consent for Participation and Donation of Blood Samples
- PIDTC 6902, A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1, 1968
- PIDTC 6901, A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders
- A Multicenter Safety Study of Unlicensed Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
- BMT CTN #1204, Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
- PIDTC Protocol # 6903, Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
- PIDTC Protocol # 6904, Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990
- BMT CTN 1202, Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
- BP-U-004, Phase I/II study of CaspaCide T Cells from an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+ T Cells in Pediatric Patients Affected by Hematological Disorders
- CMX001-351, An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
- Transition from Hospital to Home Following Hematopoietic Stem Cell Transplantation: A Feasibility Study for “Rooming In”
- GC P#05.01.020, A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies
- 10-CBA, A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) For Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Daniel Bowers

- ACNS0332, Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Prop-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.
- Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma (SJYC07)
• Evaluation of Radiation-Induced Vasculopathy by Transcranial Doppler (TCD) Among Survivors of Childhood Medulloblastoma Treated with Cranial Radiation Therapy
• "ACNS0821, Temozolomide with Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
• Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
• ACNS1123, Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
• SJMB12, A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
• H-29892, Case Ascertainment for Epidemiologic Studies of Childhood Cancers and Hematological Conditions
• ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
• CRA001CUS224T, Phase II Study of Everolimus (RAD001, AFINITOR) for Children with Recurrent or Progressive Ependymoma
• MEK162, Phase I-II Study of MEK 162 for Children with Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
• Evaluation of the Efficacy of Re-irradiation for Locally Recurrent Ependymoma [A Multi-Institutional Retrospective Chart Review]

Kathryn Dickerson

• TransIT, Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia PBMTC NMD1601
• ETB115E2201: A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients with Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia (SAA) or Recurrent Aplastic Anemia (AA)

Laura Klesse

• Bio-specimen Bank for Pediatric Tumors and Cancer Predispositions
• ACCESS/REDIAL, Case Ascertainment for Epidemiologic Studies of Childhood Cancers and Hematological Conditions Used by Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas and Reducing Ethnic Disparities in Acute Leukemias (REDIAL) Consortium
• Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis type 1 Associated Optic Pathway Gliomas
• Cardiovascular Abnormalities in Pediatric Patients with Neurofibromatosis Type 1
• Compassionate Use of Trametinib in Low Grade Glioma
• NF1 LGG Synodos: Target Identification of Neurofibromatosis Type 1 Associated Low Grade Glioma

Andrew Koh

• Role of Commensal Flora in the Development of Bacteremia and Fungemia in Cancer and Stem Cell Transplant Patients
Pediatric Hematology-Oncology 2018 Annual Report

Ted Laetsch

- 20140106 (former CFZ008), Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
- Assessing the precision of MR thermometry in Pediatric Solid Tumor Patients
- ADVL1322 (VEG116731), A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
- AOST1321, Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
- NMTRC V0706, A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
- AOST1421, A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
- "NMTRC012: A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
- (Peds-PLAN – Pediatric Advanced Precision Laboratory Advanced Neuroblastoma Therapy)"
- AAML1421, A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
- ONC-403-001, A Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma, or Alveolar Rhabdomyosarcoma
- iSB-MC-JGDN, A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
- EZH-102, A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
- NMTRC 014, NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
- ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
- APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
- ADVL1722, A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
- CDRB436G2201, Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination with Trametinib in Children and Adolescent Patients with BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
- ADVL17111, A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
- UCART19-PALL, A Phase 1, Open Label, Non-comparative, Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients with Relapsed /Refractory B-cell Acute Lymphoblastic Leukaemia
- Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)
- "CCTL019C2202, (BIANCA) A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
- M16-106, A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma (LL)
- T2014-001, A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
- ADVL1621, MK-3475-051, A Phase I/I Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
T2012-002, A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

The iCat2, GAIN Consortium Study, Multicenter Cohort Study to Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Recurrent, Refractory, or High Risk Solid Tumors

IMD2-04-1702, A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy

S47674ALL2005, An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

CCTL019B2206: A Multicenter Study of Apheresis Collection of Peripheral Blood Mononuclear Cells (PBMC) in Patients with CD19 Expressing Malignancies Who Could Be Eligible for a CCTL019 Clinical Research Trial

AAML1321 (CAMN1072203), A Multi-Center, Open Label, Non-Controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or with Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to either Imatinib or Dasatinib

LOXO-TRK-15003, A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

Pilot Study of MR-guided High Intensity Focused Ultrasound (HIFU) Hyperthermia with Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric Solid Tumors

CCTL019B2205J: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients with Relapsed and refractory B-cell Acute Lymphoblastic Leukemia

LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers

CCTL019B2003I: Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Diffuse Large B-cell Lymphoma (DLBCL) Patients without of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

Panel Based Next Generation Sequencing for High Risk Pediatric Oncology Patients

Patrick Leavey

ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer

ALTE05N1, Umbrella Long-Term Follow-up Protocol

ALTE03N1: Key Adverse Events Following Childhood Cancer

Long-term Follow-up of Patients Enrolled on Children’s Oncology Group Sponsored Research
• ALTE16C1, Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
• SPOC-2012-001, Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
• Using Imaging and Computational Tools to Improve Risk Stratification in Children with Bone Cancer
• Prospective Evaluation of the Use of Imaging and Computational Tools to Improve Risk Stratification in Children with Bone Cancer
• AEWS1031, A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
• AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
• Molecularly Targeted Therapy for Soft Tissue Sarcoma in Texas - Biospecimen Banking Protocol
• Evaluation of ctDNA as a Prognostic Biomarker for Patients with Newly Diagnosed Localized Ewing Sarcoma or Osteosarcoma
• Identification of Anxiety and Depression in Children with Cancer
• APEC14B1, Project: EveryChild- A Registry, Eligibility Screening, Biology and Outcome Study

Kathleen Ludwig

• Pediatric Hematology and Oncology Bio-Specimen Repository
• "ADV11521, A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia"

Andrew Martin

• ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Martha Pacheco

• ALTE11C1, Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
• AHOD04B1, Hodgkin Disease (HD) Banking Study
• ANHL1131, Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients
• ANHL12P1, A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117
• AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
• AHOD1721 (CA209744). Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/refractory (R/R) CD30 + Classic Hodgkin lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response
• 54179060LYM3003, A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients with Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
• Once-Weekly Intravenous Liposomal Amphotericin B (AmBisome) for Fungal Prophylaxis in Pediatric High-risk Hematologic Malignancy: A Retrospective Evaluation of Safety and Tolerability
• ICON 1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia

An Pham
Pediatric Hematology-Oncology

2018 Annual Report

- B5201002: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI 1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease
- B5201003: An Open-label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-occlusive crises (VOC) in Hospitalized Subjects with Sickle Cell Disease

Zora Rogers

- Silent Infarct Transfusion Trial (SITT)
- Pediatric Hydroxyurea Phase III Clinical Trial: BABY HUG
- Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study.
- "BABY HUG FU II: Pediatric Hydroxyurea Phase III Clinical Trial Follow-up Observational Study II
- Retrospective Study of Pediatric Aplastic Anemia
- HUGKISS: A Pilot Study of Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
- DISPLACE (Part 1): Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (Chart Review)
- Severe Chronic Neutropenia International Registry

Tiffany Simms-Waldrip

- Treatment  Use of the CliniMACS® CD34 Reagent System to Prepare Cells for an Unlabeled Indication Using an HLA-Compatible Related or Unrelated Donor for Allogenic Transplant
- 15-007, A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide Versus Best Supportive Care in the Prevention of Hepatic Veno-occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
- The Role of the Host Microbiome in the Health of Cancer and Stem Cell Transplant Patients
- Identifying Risk Factors Associated with Supra-Therapeutic Levels Following Initial Tacrolimus Dosing

Stephen Skapek

- Molecular Characterization of Childhood Cancer Specimens

Tamra Slone

- ANHL1522,A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
- AALL1131, A Phase 3 Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
- AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-Ly)
- AAML1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
- AALL1521 (INCB 18424-269), A Phase 2 Study of the JAK1 JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
- AALL15p1, A Group-wide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
- AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
- AALL0581: A Children’s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
AAML1531, Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-Ly)
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Evaluation of the Influence of Abnormal Glucose Metabolism on the Risk of Infection in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
AALL1331, Risk-stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
ANBL12P1, Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
ANBL00B1, Neuroblastoma Biology Studies
ANBL1221, A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
ANBL09P1, A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
An Open Label, Expanded Access Protocol Using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
MIBG 2014-01, A Phase II Single-Arm Study of Therapeutic Iobenguane (131I) for High Risk Neuroblastoma Subjects at the time of First Relapse
ALTE15N2, LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
"Pediatric Solid Tumor Metabolism
A Prospective, Single-center Study Exploring Solid Tumor Metabolism of Extra-Cranial Tumors in the pediatric Population
AREN03B2: Renal Tumors Classification, Biology and Banking
9442: National Wilms Tumor Late Effects Study
AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AHEP1531, Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Jonathan Wickiser
AGCT1532, A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors

Naomi Winick

- The Feasibility and Acceptability of Incorporating Electronic Assessment Tools during Outpatient Visits for Patients in the Maintenance Phase of Therapy for Acute Lymphoblastic Leukemia
- ACCL0922, (SCUSF 0901) A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
- ACCLI0P1, Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
- AALL1122, A Phase 2 Multi-Center Historically - Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Evaluation of MicroRNAs as Novel Markers of Cardiotoxicity in Children Undergoing Anthracycline Therapy for Pediatric Cancer
- Inpatient Outcomes and Chemotherapy Related Toxicities Among a National Cohort of Children with Acute Leukemia
- ACCLI033, A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
- Aim 1, Home or Away from Home: Comparing Clinical Outcomes Relevant to the Care of Pediatric Acute Myeloid Leukemia During Periods of Neutropenia
- Aim 3, Home or Away from Home: Comparing Patient and Caregiver Reported Quality of Life and Other Patient-centered Outcomes for Inpatient Versus Outpatient Management of Neutropenia in Children with AML
- The Feasibility of Delivering a Motivational Interviewing Session to Primary Caretakers of Children with Acute Lymphoblastic Leukemia (ALL) and Adolescents with ALL: Comparison to an Education-only Control.
- Assessing Neurocognitive Functioning Over Time in Pediatric Patients with Non-CNS Solid Tumors and Nonlymphoblastic Leukemia/Lymphomas
- Feasibility of Home-Based Computerized Cognitive Training during Maintenance Therapy for ALL
- ALTE1631, A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
- A Randomized Evaluation of a Six-Week Grief Curriculum for Bereaved Parents
- Risk Factors for Toxicity During the Induction and Delayed Intensification Phases of Treatment for Acute Lymphoblastic Leukemia (ALL)

Ayesha Zia

- Multicenter, Open-Label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and-body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children with Acute Venous Thromboembolism
- Evaluation of Thrombin Generation in Children with Venous Thromboembolism
- Physical Activity in Children at Risk of Post-thrombotic Syndrome: A Pilot Randomized Controlled Trial
- Outcomes after pediatric venous thromboembolism
- Thrombin Generation in Children with Sickle Cell Anemia Using Platelet-Rich Plasma and Platelet-Poor Plasma
- Comprehensive and Multidisciplinary Approach to Evaluation of Young Women with Heavy Menstrual Bleeding (HMB): Impact on Diagnosis, Management and Outcomes
- Kids-DOTT: Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children (Protocol # 03-585)
- Zimmerman Program for the Molecular and Clinical Biology of VWD
- The American Thrombosis and Hemostasis Network (ATHN)
- NN7999-3774 Safety, Efficacy and Pharmacokinetics of N9-GP in Previously Treated Children with Hemophilia B
- CDC Public Health Surveillance for Bleeding Disorders - Registry for Bleeding Disorders Surveillance
- "My Life Our Future: A Hemophilia Genotyping Initiative
- Data and Sample Research Repository"
• A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Coagulation Replacement Factor Products (ATHN-2: Switching Study)
• ATHN 4: VTE Project - Transition of Care for patients with Venous Thromboembolism (VTE) at ATHN (American Thrombosis and Hemostasis Network) Affiliated Sites
• An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIfc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients with Severe Hemophilia A
• Genotype and Phenotype Analysis of Adolescents with Heavy Menstrual Bleeding and Low von Willebrand Activity

Research Funding

Clinical and laboratory research efforts are funded by a wide variety of national, regional and local organizations, such as the NIH National Cancer Institute, National Heart, Lung, and Blood Institute, and National Eye Institute; the Cancer Research and Protection Institute of Texas; St. Baldrick's Foundation, Children’s Cancer Fund of Dallas, Children’s Medical Center Foundation, Wipe-Out Kids’ Cancer, 1 Million for Anna Foundation, the Haggerty Family Foundation, Hyundai Hope on Wheels Foundation, and the Barrett Family Center for Pediatric Cancer.

Clinical Activities

The Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Medical Center Dallas is the clinical site for most of the pediatric hematology and oncology care. The largest program of its kind in North Texas and the region, our program is internationally known for its excellence in patient care, education, clinical and laboratory research, and patient advocacy.

New sites for clinical care include the Children's Medical Center Plano hospital for outpatient clinics and inpatient delivery of scheduled chemotherapy, and the Texas Health Resources Presbyterian Hospital for general hematology clinics. Our team is developing new opportunities to augment the scope and scale of hematology and oncology services in Plano and at a new Frisco site, anticipated for the coming year.

Core Clinical Programs in Hematology and Oncology

• Brain Tumor
• Bone and Soft Tissue Sarcoma
• Bone Marrow Failure
• Genitourinary Neoplasms
• Hemophilia, Hemostasis, and Thrombosis
• Hepatoblastoma
• Histiocytoses
• Iron Deficiency and other General Hematology
• Leukemia/Lymphoma
• Neuroblastoma
• Rare Tumors
• Sickle Cell Disease/Hemoglobinopathies
• Stem Cell Transplant Programs
  o Transplant for Malignancy
  o Transplant for Non-malignant Disease
• Young Women’s Blood Disorders

Additional Clinical/Research Programs

• After the Cancer Experience (ACE) Childhood Cancer Survivor Program
• Cancer Genetic Susceptibility Program
• Neurofibromatosis
• Adolescent and Young Adult Oncology
• Experimental Therapeutics Program
• Precision Medicine Program
• Palliative Care Program

A multidisciplinary approach is used in the Gill Center to plan and deliver clinical care that is targeted to meet the needs of each child. Among the services offered are social work, child psychology/psychiatry, nutritional support, pastoral care, physical and occupational therapy, prosthetics services, and palliative care, where appropriate.
Faculty members also provide a consulting service for newborn patients with hematological conditions at Parkland Memorial Hospital, the 997-bed Dallas County hospital with approximately 16,000 newborn deliveries each year that is the site of the newborn nursery. New sites for hematology consultations include the newborn nursery at the Clements University Hospital and the Texas Health Resources Presbyterian Hospital.
Current Grant Support

James Amatruda

Grantor: CPRIT RP120685-C1
Title of Project: C1: Central Sarcoma Processing Core
Role: Principal Investigator
Dates: 09/2012 – 02/2019

Grantor: CPRIT RP120685-P3
Title of Project: P3: Functional Validation of Actionable Mutations in Sarcoma Genetic Model Systems
Role: Principal Investigator
Dates: 09/2012 – 02/2019

Grantor: Dana-Farber Institute/St. Baldrick's Subcontract #358099
Title of Project: Malignant Germ Cell Tumors International Consortium
Role: Principal Investigator
Dates: 07/2015 – 06/2020

Grantor: RP160249 CPRIT
Title of Project: DIS3L2 in Childhood Wilms Tumor: Mechanism to Medicines
Role: Collaborator (Mendell)
Dates: 03/2016 – 02/2020

Grantor: NIH 1 P50 CA196516-01-A1 (Project 4)
Title of Project: Prognostic Significance and Therapeutic Potential of DROSHA Mutations in Wilms Tumor
Role: Leader
Dates: 08/2016 – 07/2021
Pediatric Hematology-Oncology

2018 Annual Report

Grantor: Alex’s Lemonade Stand Foundation
Title of Project: DICER1-driven Cancers: Models, Mechanisms and Therapies
Role: Principal Investigator
Dates: 09/2016 – 08/2019

Grantor: 5 U10 CA 180884-03 / Children’s Hospital of Philadelphia
Title of Project: Texas Pediatric Patient Derived Xenograft Facility
Role: Co-Investigator (Adamson)
Dates: 03/2017 – 02/2018

Grantor: 5 U10 CA 180884-03 / Children’s Hospital of Philadelphia
Title of Project: NIH National Clinical Trials Network (NCTN)
Role: Subcommittee Vice-Chair
Dates: 03/2017 – 02/2018

Grantor: Baylor/CPRIT, RFA R016-CFSA-2
Title of Project: The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service
Role: Principal Investigator
Dates: 06/2016 – 05/2021

Grantor: CPRIT RP170152
Title of Project: Targeting the HNF4A and WNT/Beta-catenin pathways in childhood malignant
Role: Co-Principal Investigator
Dates: 12/2016 – 11/2020

Grantor: Baylor College of Medicine RP170071
Title of Project: Genetic Epidemiology and Molecular Basis of Cancer Predisposition
Role: Collaborator
Dates: 12/2016 – 11/2019

Grantor: NIH/NCI 1P50CA196516-01-A1
Title of Project: UTSW SPORE in Kidney Cancer Career Enhancement Program
Role: Program Director
Dates: 08/2016 – 07/2021

Grantor: Alex’s Lemonade Stand Foundation / Young Investigator
Title of Project: The role of miRNA impairment in Wilms tumor formation
Role: Mentor (Chen, Fellow)
Dates: 06/2016 – 06/2019

Grantor: NIH/NCI 1 K08 CA207849-01
Title of Project: The role of 5p miRNA loss in Wilms tumor formation
Role: Mentor (Chen, Fellow)
Dates: 07/2016 – 06/2021

Victor Aquino

Grantor: Aquino - PIDTC #6902 / Children’s Hospital Los Angeles
Title of Project: Per Case Reimbursement
Role: Principal Investigator
Dates: 04/2017 – 04/2018
Kenneth Chen

Grantor: CCRAC, Micaela’s Army Foundation
Title of Project: Replacement therapy for miRNA-impaired Wilms tumors
Role: Principal Investigator
Dates: 11/2015 – Current

Grantor: NIH/NCI 1 K08 CA207849-01
Title of Project: The Role of 5p miRNA Loss in Wilms Tumor Formation
Role: Principal Investigator
Dates: 07/2016 – 06/2021

Laura Klesse

Grantor: Southwestern Medical Foundation / Dedman Family Scholarship Fund
Title of Project: Dedman Scholar Support
Role: Principal Investigator
Dates: 3/2009 – Current

Grantor: Baylor/CPRIT, RFA R016-CFSA-2
Title of Project: The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service
Role: Co-Principal Investigator
Dates: 06/2016 – 05/2021

Grantor: The Children’s Tumor Foundation
Title of Project: Children’s Tumor Foundation Support
Role: Principal Investigator
Dates: 1/2011 – Current

Grantor: Children’s Tumor Foundation
Title of Project: Developing Evidence-Based Criteria for Initiating Treatment for NF1-OPG
Role: Principal Investigator
Dates: 12/2017 – 11/2020

Grantor: Texas Neurofibromatosis Foundation
Title of Project: Cardiovascular abnormalities in pediatric patients with neurofibromatosis type 1
Role: Principal Investigator
Dates: 06/2016 – 05/2018

Ted Laetsch

Grantor: Micaela’s Army Foundation
Title of Project: A Clinical Trial Combining Targeted Therapy for Pediatric and Young Adult Patients with Refractory Germ Cell Tumors
Role: Principal Investigator
Dates: 7/2014 – Current

Grantor: NIH 1 R01 CA199937-01
Title of Project: Image-guided doxorubicin delivery for pediatric sarcomas (MPI)
Role: Co-Investigator (Chopra)
Dates: 07/2015 – 06/2020
Grantor: University of Colorado  
**Title of Project:** A Phase I/Ib Study of Eribulin in Combination with Oral Irinotecan for Adolescent and Young Adult Patients with Relapsed or Refractory Solid Tumors  
**Role:** Principal Investigator  
**Dates:** 09/2017 – 08/2018

Grantor: Hyundai Hope on Wheels  
**Title of Project:** MR-guided High Intensity Focused Ultrasound (MR-HIFU) Hyperthermia for the Treatment of Pediatric Solid Tumors  
**Role:** Principal Investigator  
**Dates:** 01/2015 – 12/2018

Grantor: US Department of Defense  
**Title of Project:** Eliminating ex-Vivo Manipulation and Viral Transfection of T-Cells in CAR-T Cell Immunotherapy of B-Cell Malignancies  
**Role:** Co-Investigator (Lux)  
**Dates:** 07/2017 – 06/2019

Grantor: NIH / Children’s Hospital of Philadelphia  
**Title of Project:** Match Committee-NIH National Clinical Trials Network (NCTN) Grant  
**Role:** Principal Investigator  
**Dates:** 03/2018 – 02/2019

**Patrick Leavey**

Grantor: Cancer Prevention Research Institute of Texas (CPRIT)  
**Title of Project:** Molecularly Targeted Therapy for Soft Tissue Sarcoma in Texas  
**Role:** Co-Investigator and Principal Investigator Biospecimen Banking Study  
**Dates:** 9/2012 – 8/2018

Grantor: Cancer Prevention Research Institute of Texas (CPRIT)  
**Title of Project:** Using Imaging and Computational Tools to Improve Risk Stratification in Children with Bone Cancer  
**Role:** Principal Investigator  
**Dates:** 3/2015 – 2/2019

Grantor: Cancer Prevention Research Institute of Texas (CPRIT)  
**Title of Project:** Leavey - CPRIT IIRACCA  
**Role:** Principal Investigator  
**Dates:** 4/2014 – 2/2019

**Zora Rogers**

Grantor: NIH/St. Jude Children’s Research Hospital  
**Title of Project:** Hydroxyurea Management in Kids: Intensive versus Stable Dosage Strategies“ (HUG KISS)  
**Role:** Principal Investigator  
**Dates:** 04/2016 – 03/2019

Grantor: Medical University of South Carolina  
**Title of Project:** DISPLACE: Dissemination and Implementation of Stroke Prevention: Looking at the Care Environment  
**Role:** Principal Investigator  
**Dates:** 07/01/2017- 06/30/2018
Stephen Skapek

Grantor: NIH/NEI
Title of Project: Tgfβ2 Controls p19Arf During Eye Development
Role: Principal Investigator

Grantor: NIH/NCI
Title of Project: Cancer Center Support Grant
Role: Co-Investigator
Dates: 8/2015 – 7/2020

Grantor: Cancer Prevention Research Institute of Texas (CPRIT)
Title of Project: Molecularly Targeted Therapy for Soft Tissue Sarcoma in Texas
Role: Principal Investigator
Dates: 9/2012 – 2/2019

Grantor: St. Baldrick’s Foundation
Title of Project: Targeting LILRB4 by CAR-T cells for the treatment of pediatric AML
Role: Mentor
Dates: 07/2016 – 06/2019

Grantor: Cancer Prevention Research Institute of Texas (CPRIT)/UTHSCSA
Title of Project: Texas Pediatric Patient Derived Xenograft Facility
Role: Co-Investigator
Dates: 06/2016 – 05/2021

Grantor: NIH
Title of Project: Physician Scientist Oncology Training Program
Role: Principal Investigator
Dates: 09/2009 – 08/2019

Grantor: NIH/NCI P30 CA142543
Title of Project: Cancer Center Support Grant
Role: Co-Leader of Development and Cancer Scientific Program
Dates: 08/2010 – 07/2020

Grantor: Indiana University
Title of Project: Developmental and Hyperactive RAS Tumor SPORE; Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumor
Role: Co-Leader Project 2
Dates: 09/2015 – 08/30/2020

Grantor: CHOP/NIC (NCI) U10CA180884
Title of Project: COG NCTN Solid Malignancy Integrated Translational Science Center
Role: Principal Investigator/MP1
Dates: 03/2016 – 02/2018
Grantor: NIH/NHLBI  
Title of Project: Predicting and Preventing Poor Outcomes of Venous Thromboembolism in Children  
Role: Co-Principal Investigator  
Dates: 05/2016 – 04/2021

Grantor: CHOP/NIH (NCI) UM1CA097452  
Title of Project: COG Phase 1 Pilot Consortium  
Role: Principal Investigator  
Dates: 05/2017 – 03/2018

Grantor: CHOP/NIH U10CA180886  
Title of Project: NIH NCTN Scientific Council  
Role: Principal Investigator  
Dates: 03/2017 – 02/2019

Grantor: CPRIT RP120685-AC  
Title of Project: AC: Molecularly Targeted Therapy for Soft Tissue Sarcoma  
Role: Principal Investigator  
Dates: 09/2012 – 02/2019

Grantor: CPRIT RP120685-P2  
Title of Project: P2: High Throughput Screening for Sarcoma Cell Proliferation and Survival Factors  
Role: Principal Investigator  
Dates: 09/2012 – 02/2019

Tanya Watt  
Grantor: South Plains Oncology Consortium  
Title of Project: SPOC 2014-001 Expanded Access Study of Fenretinide  
Role: Principal Investigator  
Dates: 03/01/2015 - 02/28/2018

Ayesha Zia  
Grantor: NIH/NHLBI  
Title of Project: Predicting and Preventing Poor Outcomes of Venous Thromboembolism in Children  
Role: Principal Investigator  
Dates: 05/2016 – 04/2021

Grantor: Blood Center of Wisconsin, Inc. (NIH-NHLBI Flowthrough)  
Title of Project: Comparative Effectiveness in the Diagnosis of VWD  
Role: Principal Investigator  
Dates: 12/2013 – 11/2018

Grantor: UT Health Science Center at Houston  
Title of Project: HTC- Great Plains Regional Hemophilia Network  
Role: Principal Investigator  
Dates: 06/2017 – 05/2018

Grantor: UT Health Science Center at Houston  
Title of Project: HTC- Great Plains Regional Hemophilia Network  
Role: Principal Investigator  
Dates: 06/2017 – 05/2018
Grantor: All Children’s Hospital  
Title of Project: Kids-DOTT  
Role: Principal Investigator  
Dates: 04/2017 – 04/2018

Grantor: American Thrombosis & Hemostasis Network  
Title of Project: A Longitudinal Observational Study of Previously Treated Hemophilia Patients  
Role: Principal Investigator  
Dates: 07/2017 – 06/2018

Yanbin Zheng

Grantor: NIH / NEI  
Title of Project: Tgf Beta 2 controls p19Arf During Eye Development  
Role: Co-Investigator  
Dates: 4/2014 – 3/2018

Grantor: Andrew McDonough B+ Foundation  
Title of Project: Developing a novel therapeutic strategy for rhabdomyosarcoma  
Role: Principal Investigator  
Dates: 1/2019 – 12/2020

Peer-Reviewed Publications


